Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2001Science

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

View Full Paper
Ask AI
Bookmark
Share

Authors

MGM. GorreCombiMatrixKEKatharine EllwoodUniversity of California, Los AngelesNHNicholas C. HsuKaohsiung Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gorre et al. (2001) studied this question.

synapsesocial.com/papers/6a7dbf18c108c8d3ff045756https://doi.org/10.1126/science.1062538
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase2000 · 1,801 citations
  2. 2Role of alpha1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI5712000 · 323 citations
  3. 3Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines2000 · 399 citations
  4. 4Induction of Chronic Myelogenous Leukemia in Mice by the P210 <sup> <i>bcr/abl</i> </sup> Gene of the Philadelphia Chromosome1990 · 2,203 citations
  5. 5Chronic Myeloid Leukemia1999 · 1,638 citations